BOAST
发表于 2025-3-26 22:39:29
https://doi.org/10.1057/9780230299009ance on the recommended practices for key aspects of supportive care and their implementation in a new transplant unit, including intravenous access, intensive care, antiemetic and pain relief, management of mucositis, nutritional support, drug toxicity, and anti-infective management.
个人长篇演说
发表于 2025-3-27 04:10:24
http://reply.papertrans.cn/32/3158/315744/315744_32.png
姑姑在炫耀
发表于 2025-3-27 08:04:37
d laboratory analyses improve the safety of blood products and allow appropriate donor selection, thus avoiding blood-transmissible diseases. To reduce relapse risk after HSCT, the assessment of minimal residual disease enables timely therapeutic measures to be taken to eradicate malignant cells in the long term.
CLEAR
发表于 2025-3-27 10:53:14
http://reply.papertrans.cn/32/3158/315744/315744_34.png
美丽的写
发表于 2025-3-27 14:17:58
Transfusion,donor is generally high, approximately 40–50%. Immune-related hemolysis is a commonly encountered complication. In this chapter, we focus on practical guides for the selection and management of the transfusion products required in HSCT from an ABO or Rh blood type–incompatible donor. Practical examples, Tables, and a Format are provided.
cavity
发表于 2025-3-27 20:24:35
Laboratory Support,d laboratory analyses improve the safety of blood products and allow appropriate donor selection, thus avoiding blood-transmissible diseases. To reduce relapse risk after HSCT, the assessment of minimal residual disease enables timely therapeutic measures to be taken to eradicate malignant cells in the long term.
考博
发表于 2025-3-27 22:34:33
http://reply.papertrans.cn/32/3158/315744/315744_37.png
overrule
发表于 2025-3-28 02:20:00
978-3-319-86606-2Springer International Publishing AG 2018
condescend
发表于 2025-3-28 07:24:05
Timothy J. Ellender,Joseph R. Shiber0 years to arrive at this point, with many setbacks occurring along the way. Today, absolute transplant numbers and transplant rates (TR; number of HSCTs per number of inhabitants) vary significantly between centers, countries, and global regions. Recent investigations have shed light on some factor
争吵加
发表于 2025-3-28 13:17:34
https://doi.org/10.1007/978-94-009-6036-7000 patients per year, and worldwide activity continues to increase steadily. For many hematological and non-hematological diseases HSCT remains the only curative treatment option. Improved understanding of the immunological mechanisms of tolerance and anti-tumor reactivity has markedly reduced tran